Question 1

What is the analyst consensus rating for TRVI?

Accepted Answer

The analyst consensus rating for TRVI is "Buy" based on 4 analyst recommendations.

Question 2

What is the average price target for TRVI?

Accepted Answer

The average 12-month price target for TRVI is $18.50, representing an upside of 82.3% from the current price of $10.15.

Question 3

What do analyst ratings mean?

Accepted Answer

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

Question 4

What is a price target?

Accepted Answer

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.

Date	Analyst	Firm	Action	Rating	Price Target
Jan 9, 2026	Brandon Folkes	HC Wainwright	Reiterates	Strong Buy	$21.00 → $21.00 +0.00 (0.0%)
Jan 8, 2026	Jason Kolbert	D Boral Capital	Maintains	Strong Buy	$19.00 → $19.00 +0.00 (0.0%)
Dec 19, 2025	Annabel Samimy	Stifel	Maintains	Strong Buy	$15.00 → $18.00 +3.00 (20.0%)
Nov 20, 2025	Faisal Khurshid	Leerink Partners	Maintains	Buy	$13.00 → $16.00 +3.00 (23.1%)

Trevi Therapeutics (TRVI) Stock Analyst Forecast

Analyst Consensus Rating

Consensus Rating

Average Price Target

Latest TRVI Analyst Ratings & Recommendations